A compilation of research working groups on drug utilisation across Europe.

Tjeerd Van Staa; Juan Fernando Pacheco; Hans Petri; Joan-Ramon Laporte; Y Alvarez; J Slattery; X Kurz; G Candoere; J Durand; S Blackburn; M Rottenkolber; J Hasford; A Stueven; F J de Abajo Iglesias; E Martin Merino; M Gil; C Huerta; G Requena; B Oliva; D Montero; L A Garcia-Rodriguez; A Ruigomez; P C Souverein; L van Dijk; A Afonso; M De Groot; H Gardarsdottir; F Rutten; R Van den Ham; S Belitser; A de Boer; R Groenwold; A Sanni; J Uddin; O Klungel; D De Bakker; W Pestman; K Roes; A Hoes; V Abbing-Krahagopian; F De Vries; T P van Staa; A C G Egberts; H G M Leufkens; O H Klungel; I Teixidor; J Parkinson; P Helboe; J Lyngvig; A M Clemensen; T S Engraff; U Hesse; J Poulsen; P F Rønn; J Logie; J Pimenta; K Davis; E J Swain; L Abenhaim; D Neasham; R F Reynolds; N Gatto; A Bate; J Richards; G F Downey; R Brauer; M Schoonen; A Roddam; E Velthuis; O Demol; M Miret; S Johansson; P Primatesta; R Schlienger; J Fortuny; E Rivero; J Weil; E Plana Hortoneda; G Quartey; I Tatt; J Hannon; J Robinson; S Vesanen; J R Laporte; L Ibáñez; M Sabaté; E Ballarín; M Pérez; P Ferrer; S Schmiedl

doi:10.1186/1756-0500-7-143

A compilation of research working groups on drug utilisation across Europe.

Tjeerd Van Staa, Juan Fernando Pacheco, Hans Petri, Joan-Ramon Laporte, Y Alvarez (Collaborator), J Slattery (Collaborator), X Kurz (Collaborator), G Candoere (Collaborator), J Durand (Collaborator), S Blackburn (Collaborator), M Rottenkolber (Collaborator), J Hasford (Collaborator), A Stueven (Collaborator), F J de Abajo Iglesias (Collaborator), E Martin Merino (Collaborator), M Gil (Collaborator), C Huerta (Collaborator), G Requena (Collaborator), B Oliva (Collaborator), D Montero (Collaborator)L A Garcia-Rodriguez (Collaborator), A Ruigomez (Collaborator), P C Souverein (Collaborator), L van Dijk (Collaborator), A Afonso (Collaborator), M De Groot (Collaborator), H Gardarsdottir (Collaborator), F Rutten (Collaborator), R Van den Ham (Collaborator), S Belitser (Collaborator), A de Boer (Collaborator), R Groenwold (Collaborator), A Sanni (Collaborator), J Uddin (Collaborator), O Klungel (Collaborator), D De Bakker (Collaborator), W Pestman (Collaborator), K Roes (Collaborator), A Hoes (Collaborator), V Abbing-Krahagopian (Collaborator), F De Vries (Collaborator), T P van Staa (Collaborator), A C G Egberts (Collaborator), H G M Leufkens (Collaborator), O H Klungel (Collaborator), I Teixidor (Collaborator), J Parkinson (Collaborator), P Helboe (Collaborator), J Lyngvig (Collaborator), A M Clemensen (Collaborator), T S Engraff (Collaborator), U Hesse (Collaborator), J Poulsen (Collaborator), P F Rønn (Collaborator), J Logie (Collaborator), J Pimenta (Collaborator), K Davis (Collaborator), E J Swain (Collaborator), L Abenhaim (Collaborator), D Neasham (Collaborator), R F Reynolds (Collaborator), N Gatto (Collaborator), A Bate (Collaborator), J Richards (Collaborator), G F Downey (Collaborator), R Brauer (Collaborator), M Schoonen (Collaborator), A Roddam (Collaborator), E Velthuis (Collaborator), O Demol (Collaborator), M Miret (Collaborator), S Johansson (Collaborator), P Primatesta (Collaborator), R Schlienger (Collaborator), J Fortuny (Collaborator), E Rivero (Collaborator), J Weil (Collaborator), E Plana Hortoneda (Collaborator), G Quartey (Collaborator), I Tatt (Collaborator), J Hannon (Collaborator), J Robinson (Collaborator), S Vesanen (Collaborator), J R Laporte (Collaborator), L Ibáñez (Collaborator), M Sabaté (Collaborator), E Ballarín (Collaborator), M Pérez (Collaborator), P Ferrer (Collaborator), S Schmiedl (Collaborator)

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published. As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five selected groups of medicines, we aimed to identify and describe the main characteristics of the existing collaborative European working groups. FINDINGS: Google and bibliographic searches (PubMed) of articles containing information on databases and other sources of drug consumption data were conducted. For each working group the main characteristics were recorded.Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE'S SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE), b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe). Information on their aims, methods and activities is presented. CONCLUSIONS: We assembled and updated information on European working groups in DU research and in the utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting post-authorisation and safety studies. European health authorities should encourage national research and collaborations in this important field for public health.

Original language	English
Journal	BMC Research Notes
Volume	7
DOIs	https://doi.org/10.1186/1756-0500-7-143
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1756-0500-7-143

Cite this

Van Staa, T., Pacheco, J. F., Petri, H., Laporte, J.-R., Alvarez, Y., Slattery, J., Kurz, X., Candoere, G., Durand, J., Blackburn, S., Rottenkolber, M., Hasford, J., Stueven, A., Iglesias, F. J. D. A., Merino, E. M., Gil, M., Huerta, C., Requena, G., Oliva, B., ... Schmiedl, S. (2014). A compilation of research working groups on drug utilisation across Europe. BMC Research Notes, 7. https://doi.org/10.1186/1756-0500-7-143

@article{811c7f3a4c274af4be71f991d0c4c155,

title = "A compilation of research working groups on drug utilisation across Europe.",

abstract = "BACKGROUND: The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published. As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five selected groups of medicines, we aimed to identify and describe the main characteristics of the existing collaborative European working groups. FINDINGS: Google and bibliographic searches (PubMed) of articles containing information on databases and other sources of drug consumption data were conducted. For each working group the main characteristics were recorded.Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE'S SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE), b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe). Information on their aims, methods and activities is presented. CONCLUSIONS: We assembled and updated information on European working groups in DU research and in the utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting post-authorisation and safety studies. European health authorities should encourage national research and collaborations in this important field for public health.",

author = "{Van Staa}, Tjeerd and Pacheco, {Juan Fernando} and Hans Petri and Joan-Ramon Laporte and Y Alvarez and J Slattery and X Kurz and G Candoere and J Durand and S Blackburn and M Rottenkolber and J Hasford and A Stueven and Iglesias, {F J de Abajo} and Merino, {E Martin} and M Gil and C Huerta and G Requena and B Oliva and D Montero and Garcia-Rodriguez, {L A} and A Ruigomez and Souverein, {P C} and {van Dijk}, L and A Afonso and {De Groot}, M and H Gardarsdottir and F Rutten and {Van den Ham}, R and S Belitser and {de Boer}, A and R Groenwold and A Sanni and J Uddin and O Klungel and {De Bakker}, D and W Pestman and K Roes and A Hoes and V Abbing-Krahagopian and {De Vries}, F and {van Staa}, {T P} and Egberts, {A C G} and Leufkens, {H G M} and Klungel, {O H} and I Teixidor and J Parkinson and P Helboe and J Lyngvig and Clemensen, {A M} and Engraff, {T S} and U Hesse and J Poulsen and R{\o}nn, {P F} and J Logie and J Pimenta and K Davis and Swain, {E J} and L Abenhaim and D Neasham and Reynolds, {R F} and N Gatto and A Bate and J Richards and Downey, {G F} and R Brauer and M Schoonen and A Roddam and E Velthuis and O Demol and M Miret and S Johansson and P Primatesta and R Schlienger and J Fortuny and E Rivero and J Weil and Hortoneda, {E Plana} and G Quartey and I Tatt and J Hannon and J Robinson and S Vesanen and Laporte, {J R} and L Ib{\'a}{\~n}ez and M Sabat{\'e} and E Ballar{\'i}n and M P{\'e}rez and P Ferrer and S Schmiedl",

year = "2014",

doi = "10.1186/1756-0500-7-143",

language = "English",

volume = "7",

journal = "BMC Research Notes",

issn = "1756-0500",

publisher = "Springer Nature",

}

Van Staa, T, Pacheco, JF, Petri, H, Laporte, J-R, Alvarez, Y, Slattery, J, Kurz, X, Candoere, G, Durand, J, Blackburn, S, Rottenkolber, M, Hasford, J, Stueven, A, Iglesias, FJDA, Merino, EM, Gil, M, Huerta, C, Requena, G, Oliva, B, Montero, D, Garcia-Rodriguez, LA, Ruigomez, A, Souverein, PC, van Dijk, L, Afonso, A, De Groot, M, Gardarsdottir, H, Rutten, F, Van den Ham, R, Belitser, S, de Boer, A, Groenwold, R, Sanni, A, Uddin, J, Klungel, O, De Bakker, D, Pestman, W, Roes, K, Hoes, A, Abbing-Krahagopian, V, De Vries, F, van Staa, TP, Egberts, ACG, Leufkens, HGM, Klungel, OH, Teixidor, I, Parkinson, J, Helboe, P, Lyngvig, J, Clemensen, AM, Engraff, TS, Hesse, U, Poulsen, J, Rønn, PF, Logie, J, Pimenta, J, Davis, K, Swain, EJ, Abenhaim, L, Neasham, D, Reynolds, RF, Gatto, N, Bate, A, Richards, J, Downey, GF, Brauer, R, Schoonen, M, Roddam, A, Velthuis, E, Demol, O, Miret, M, Johansson, S, Primatesta, P, Schlienger, R, Fortuny, J, Rivero, E, Weil, J, Hortoneda, EP, Quartey, G, Tatt, I, Hannon, J, Robinson, J, Vesanen, S, Laporte, JR, Ibáñez, L, Sabaté, M, Ballarín, E, Pérez, M, Ferrer, P & Schmiedl, S 2014, 'A compilation of research working groups on drug utilisation across Europe.', BMC Research Notes, vol. 7. https://doi.org/10.1186/1756-0500-7-143

TY - JOUR

T1 - A compilation of research working groups on drug utilisation across Europe.

AU - Van Staa, Tjeerd

AU - Pacheco, Juan Fernando

AU - Petri, Hans

AU - Laporte, Joan-Ramon

A2 - Alvarez, Y

A2 - Slattery, J

A2 - Kurz, X

A2 - Candoere, G

A2 - Durand, J

A2 - Blackburn, S

A2 - Rottenkolber, M

A2 - Hasford, J

A2 - Stueven, A

A2 - Iglesias, F J de Abajo

A2 - Merino, E Martin

A2 - Gil, M

A2 - Huerta, C

A2 - Requena, G

A2 - Oliva, B

A2 - Montero, D

A2 - Garcia-Rodriguez, L A

A2 - Ruigomez, A

A2 - Souverein, P C

A2 - van Dijk, L

A2 - Afonso, A

A2 - De Groot, M

A2 - Gardarsdottir, H

A2 - Rutten, F

A2 - Van den Ham, R

A2 - Belitser, S

A2 - de Boer, A

A2 - Groenwold, R

A2 - Sanni, A

A2 - Uddin, J

A2 - Klungel, O

A2 - De Bakker, D

A2 - Pestman, W

A2 - Roes, K

A2 - Hoes, A

A2 - Abbing-Krahagopian, V

A2 - De Vries, F

A2 - van Staa, T P

A2 - Egberts, A C G

A2 - Leufkens, H G M

A2 - Klungel, O H

A2 - Teixidor, I

A2 - Parkinson, J

A2 - Helboe, P

A2 - Lyngvig, J

A2 - Clemensen, A M

A2 - Engraff, T S

A2 - Hesse, U

A2 - Poulsen, J

A2 - Rønn, P F

A2 - Logie, J

A2 - Pimenta, J

A2 - Davis, K

A2 - Swain, E J

A2 - Abenhaim, L

A2 - Neasham, D

A2 - Reynolds, R F

A2 - Gatto, N

A2 - Bate, A

A2 - Richards, J

A2 - Downey, G F

A2 - Brauer, R

A2 - Schoonen, M

A2 - Roddam, A

A2 - Velthuis, E

A2 - Demol, O

A2 - Miret, M

A2 - Johansson, S

A2 - Primatesta, P

A2 - Schlienger, R

A2 - Fortuny, J

A2 - Rivero, E

A2 - Weil, J

A2 - Hortoneda, E Plana

A2 - Quartey, G

A2 - Tatt, I

A2 - Hannon, J

A2 - Robinson, J

A2 - Vesanen, S

A2 - Laporte, J R

A2 - Ibáñez, L

A2 - Sabaté, M

A2 - Ballarín, E

A2 - Pérez, M

A2 - Ferrer, P

A2 - Schmiedl, S

PY - 2014

Y1 - 2014

N2 - BACKGROUND: The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published. As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five selected groups of medicines, we aimed to identify and describe the main characteristics of the existing collaborative European working groups. FINDINGS: Google and bibliographic searches (PubMed) of articles containing information on databases and other sources of drug consumption data were conducted. For each working group the main characteristics were recorded.Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE'S SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE), b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe). Information on their aims, methods and activities is presented. CONCLUSIONS: We assembled and updated information on European working groups in DU research and in the utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting post-authorisation and safety studies. European health authorities should encourage national research and collaborations in this important field for public health.

AB - BACKGROUND: The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published. As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five selected groups of medicines, we aimed to identify and describe the main characteristics of the existing collaborative European working groups. FINDINGS: Google and bibliographic searches (PubMed) of articles containing information on databases and other sources of drug consumption data were conducted. For each working group the main characteristics were recorded.Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE'S SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE), b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe). Information on their aims, methods and activities is presented. CONCLUSIONS: We assembled and updated information on European working groups in DU research and in the utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting post-authorisation and safety studies. European health authorities should encourage national research and collaborations in this important field for public health.

U2 - 10.1186/1756-0500-7-143

DO - 10.1186/1756-0500-7-143

M3 - Article

C2 - 24625054

SN - 1756-0500

VL - 7

JO - BMC Research Notes

JF - BMC Research Notes

ER -

A compilation of research working groups on drug utilisation across Europe.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this